Hans-Georg Wirsching
University Hospital and University of Zurich
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hans-Georg Wirsching as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05664464 · Glutamate Inhibitors in GlioblastomaUniversity of Zurich · recruiting · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:53 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.Clin Cancer Res · 2015278 citationsRCR 9.4
- Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.Neuro Oncol · 2016211 citationsRCR 8.3
- 64 citationsRCR 2.6
- MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.Clin Cancer Res · 202130 citationsRCR 1.8